Abstract
Atrial fibrillation (AF) is a common co-morbidity among patients undergoing Transcatheter Aortic Valve Implantation (TAVI). Only recently have the clinical outcomes of patients with chronic or new-onset AF after TAVI been reported. The absence of clinical trials focusing on this cohort of patients has resulted in the lack of evidence based clinical guidelines. We aim to review and discuss the current literature on AF in TAVI, its clinical implications and future perspectives.
MeSH terms
-
Aged
-
Aged, 80 and over
-
Aortic Valve
-
Atrial Fibrillation* / epidemiology
-
Atrial Fibrillation* / etiology
-
Bicuspid Aortic Valve Disease
-
Cardiac Catheterization* / adverse effects
-
Cardiac Catheterization* / instrumentation
-
Cardiac Catheterization* / methods
-
Female
-
Heart Defects, Congenital / epidemiology
-
Heart Defects, Congenital / therapy*
-
Heart Valve Diseases / epidemiology
-
Heart Valve Diseases / therapy*
-
Heart Valve Prosthesis*
-
Humans
-
Male
-
Middle Aged
-
Postoperative Complications* / epidemiology
-
Postoperative Complications* / etiology